MCL Literature Feed

This review details the oncogenic role of the FoxO1 transcription factor in MCL, highlighting its potential as a novel therapeutic target with specific preclinical inhibitors under investigation.

This review details how MCL cell adhesion within the microenvironment promotes survival, explaining the mechanism of action for TME-disrupting therapies and its role in drug resistance.

This case report describes a rare presentation of primary thyroid MCL causing life-threatening airway compromise, emphasizing its inclusion in the differential diagnosis for rapidly enlarging neck masses.

This long-term Italian study confirms poor outcomes for allo-HSCT in relapsed/refractory MCL (27% 3-year PFS), with no survival benefit if not in complete remission pre-transplant.

This SHINE trial analysis shows ibrutinib's PFS benefit with BR is consistent across exposure levels, supporting dose reductions for toxicities like atrial fibrillation without compromising efficacy.

This review summarizes advanced 3D culture models that better mimic the MCL microenvironment, offering improved platforms for preclinical drug screening and developing personalized medicine.

This Danish nationwide study confirms blastoid morphology, high Ki67, and high CNS-IPI as key risk factors for secondary CNS lymphoma, supporting consideration of upfront CNS screening in high-risk patients.

This study demonstrates the feasibility of administering brexucabtagene autoleucel in an outpatient setting for MCL, a significant shift that could improve patient convenience and reduce healthcare costs.

In a US community setting, real-world data shows MCL patients on zanubrutinib had significantly longer treatment duration and adherence compared to acalabrutinib and ibrutinib, suggesting better persistence.

A 2022 real-world Japanese study shows chemotherapy remains dominant frontline while BTKis are common second-line, with physicians prioritizing quality of life for BTKi-treated patients over tumor response.

Adding venetoclax to RBAC chemo-immunotherapy improves 2-year progression-free survival to 60% for older, high-risk MCL patients, validating a new risk-stratified, fixed-duration frontline treatment.

NCCN guidelines now highlight BTK inhibitor-based regimens as effective options for high-risk, TP53-mutated classical mantle cell lymphoma, formalizing a key strategy for this difficult-to-treat population.

Acalabrutinib plus rituximab successfully resolved paraneoplastic glomerulonephritis in an MCL patient, offering a new treatment approach for this rare renal complication.

The EHA-EU MCL network published comprehensive guidelines standardizing risk-stratified diagnosis and treatment for MCL, covering young/fit and elderly patients in both frontline and relapsed/refractory settings.

Light-chain-restricted hematogones in bone marrow can mimic MCL on flow cytometry, creating a significant diagnostic pitfall that could lead to misdiagnosis or incorrect staging assessments.

In newly diagnosed MCL, ATM deletion predicts shorter progression-free survival in TP53 wild-type patients, whereas ATM mutation may indicate a better prognosis, highlighting their distinct prognostic roles.

All BTK inhibitors impair platelet aggregation in MCL as a class effect, regardless of BTK specificity or dose, providing a clear mechanism for the bleeding risk seen with these agents.

Preclinical research shows ibrutinib inhibits poxvirus replication by targeting BTK, suggesting a potential secondary antiviral benefit for immunocompromised MCL patients receiving this therapy.

Single-cell analysis reveals pre-existing minor clones with unique mutations drive relapse, explaining patient-specific progression and the need to target intratumoral heterogeneity at diagnosis.

High-throughput sequencing accurately identifies IGHV somatic hypermutation status, a key prognostic biomarker in MCL, even in complex, multi-clonal samples, improving risk stratification and MRD tracking.

This transcriptomic study uses mantle cell lymphoma as a comparator to define effusion-based lymphoma as a distinct, post-germinal center entity driven by chronic inflammatory signaling pathways.

A novel 3D bioprinted hydrogel model improves primary MCL cell survival ex vivo, offering a more physiologically relevant platform for preclinical drug screening and studying the tumor microenvironment.

ctDNA sequencing in relapsed/refractory MCL identifies SMARCA4 and TP53 mutations as response predictors and offers more sensitive MRD monitoring than qPCR, improving non-invasive risk stratification.

Ibrutinib can cause rare but severe hepatic subcapsular hematomas in relapsed MCL; ultrasound is a key tool for early diagnosis and monitoring of this bleeding complication.

Comprehensive cfDNA analysis non-invasively tracks MCL disease burden and detects high-risk mutations, offering a powerful liquid biopsy tool for monitoring and risk stratification.

BRG1-driven suppression of ferroptosis is a key mechanism of BTKi resistance in MCL, and pharmacologic BRG1 inhibition restores BTKi sensitivity, suggesting a new combination therapy.

Cyclin D1 overexpression induces replication stress and a dependency on POLQ-mediated DNA repair, identifying POLQ inhibition as a novel, targeted therapeutic strategy for mantle cell lymphoma.

Nodal MCL with leukemic presentation is a high-risk subtype characterized by SOX11-negativity, increased TP53 alterations, and inferior overall survival, requiring distinct clinical consideration.

Real-world data on commercially insured B-cell NHL patients, including MCL, reveals a 48% relapse rate at 12 months post-CAR-T, with subsequent therapies incurring significant patient out-of-pocket costs.

This review argues that new agents like BTKi are disrupting the frontline MCL standard of care, challenging ASCT's role and demanding personalized, risk-adapted treatment guidelines to resolve clinical uncertainty.